Sight Sciences Reports Strong Q4, Reduced Losses, and Positive 2026 Revenue Guidance

summarizeSummary

Sight Sciences, Inc. reported a return to revenue growth in Q4 2025, significantly reduced its net loss, and provided optimistic revenue guidance for 2026, driven by targeted investments in its Interventional Dry Eye segment.

check_boxKey Events

• Q4 2025 Revenue Growth

  Reported $20.4 million in Q4 2025 revenue, a 7% increase year-over-year, matching analyst estimates.

• Significant Loss Reduction

  Net loss for Q4 2025 decreased to $4.2 million ($0.08 per share) from $11.8 million ($0.23 per share) in the prior year.

• Strong Cash Position

  Ended 2025 with $92.0 million in cash and cash equivalents, with reduced cash usage to $0.4 million in Q4.

• Positive 2026 Revenue Guidance

  Projected full-year 2026 revenue between $82 million and $88 million, representing 6% to 14% growth compared to full year 2025.

auto_awesomeAnalysis

The company's Q4 2025 results demonstrate improved financial performance, with a 7% year-over-year revenue increase and a substantial reduction in net loss. This positive momentum is expected to continue into 2026, as evidenced by the projected 6% to 14% revenue growth. The strategic increase in operating expenses for 2026, focused on market access and commercial resources for Interventional Dry Eye, indicates a clear growth strategy. Investors should monitor the execution of these investments and the continued expansion of the Interventional Dry Eye segment.